...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Events

NextBB, along those lines since you brought it up, I have been thinking for a while that one potential scenario might be that Zenith is working on a deal for Zen-3694. The upfront money from a sale would probably be enough for ZCC to then invest that money in RVX and see BetOnMace through to the end as well as fund at least the CKD work if not more. In this scenario I would see Eastern getting more warrants to continue guaranteeing the Citi loan. Given Easterns' 38% interest in ZCC I think they would be all over a structure like this as it would increase their real interest in RVX from both sides of an arrangement like this. Who knows though, just speculation and one can see a lot of other scenarios as well. 

Share
New Message
Please login to post a reply